Vaccine Adjuvants Market To Reach USD 769.4 Million by 2021 – Increasing Investment In vaccine immunization

Vaccine Adjuvants Market

What This Report Will Provide?

The global vaccine adjuvants market consists of human and veterinary adjuvants that are used to improve the efficacy of vaccines. This market is driven by several factors such as increasing government funding for research, high prevalence of diseases, expanding biotechnology and biopharmaceutical industries, and growing focus on prevention of diseases. The high growth potential in emerging markets has opened an array of opportunities for the market. However, the high cost of adjuvant-based research and proven safety of adjuvants are hampering the growth of the global market.

Expected Revenue Growth:

[156 Pages Report] The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%.

Major Growth Boosters:

The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.

Download PDF Brochure:

Target Audience for this Report:

  • Vaccine adjuvants manufacturers and suppliers
  • Academic research institutes
  • Biopharmaceutical and biotechnology companies
  • Research and development (R&D) companies
  • Business research and consulting service providers
  • Medical research laboratories
  • Academic medical centers and universities

Value Addition for the Buyer:

This report aims to provide insights into the global vaccine adjuvants market. It provides valuable information on the product type, route of administration, disease type, applications, and application categories in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.

Request Sample Report:

On the basis of product type, the market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and other adjuvants. The particulate adjuvants segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. High prevalence of infectious diseases and increasing funding for adjuvant research will drive the growth of this market segment.

Regional Growth Analysis:

Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries.